Lonza Biologics Inc.

Neok Bio launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.

Qurient has signed a licensing agreement with Synaffix to develop a dual-payload ADC combining Qurient's CDK7 inhibitor mocaciclib with Synaffix's exatecan-based technology.

RION has engaged Lonza to provide cGMP manufacturing and technical support for commercial-scale production of its Purified Exosome Product (PEP) drug substance at Lonza's Houston facility.

Vertex Pharmaceuticals announced a reimbursement agreement with Italy's Medicines Agency (AIFA) for Casgevy, the first CRISPR/Cas9 gene-edited therapy approved for transfusion-dependent beta thalassemia and sickle cell disease in Europe.

ToolGen has filed a patent infringement lawsuit in the Netherlands against Lonza, alleging unauthorized use of its CRISPR-Cas9 RNP technology in producing CASGEVY, the world's first approved gene-editing therapy.

Lonza, Excellos, and Akadeum Life Sciences have announced a collaborative project aimed at redefining cell therapy manufacturing standards by focusing on starting material quality and integrated workflows.

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Galapagos' GLPG5101, a second-generation anti-CD19/4-1BB CAR-T therapy for relapsed/refractory mantle cell lymphoma.

Akadeum Life Sciences closed a $20 million+ financing round led by Michigan Capital Network to scale commercial operations and support customers entering clinical trials.

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.

Ethris has secured $5 million in funding from CEPI to advance the development of spray-dried RNA vaccines that remain stable at room temperature and are suitable for mucosal delivery.